cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bridgebio Pharma Inc
15 own
17 watching
Current Price
$27.06
$0.36
(1.35%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,613.49M
52-Week High
52-Week High
44.32000
52-Week Low
52-Week Low
21.62000
Average Volume
Average Volume
0.85M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,613.49M
icon52-Week High44.32000
icon52-Week Low21.62000
iconAverage Volume0.85M
iconDividend Yield--
iconP/E Ratio--
What does the Bridgebio Pharma Inc do?
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing BBP-418, a substrate supplementation therapy for the treatment of limb-girdle muscular dystrophy type 2i. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Read More
How much money does Bridgebio Pharma Inc make?
News & Events about Bridgebio Pharma Inc.
TipRanks Financial Blog
1 year ago
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO Research Report) and Arcell... Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO Research Report) and Arcellx...
Stock Options Channel
1 year ago
Investors eyeing a purchase of BridgeBio Pharma Inc (BBIO) shares, but cautious about paying the going market price of 15.56/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at ...
PR Newswire
1 year ago
Thinking about buying stock in Western Alliance Bancorp, Genprex, Windtree Therapeutics, BridgeBio Pharma, or PacWest Bancorp? Thinking about buying stock in Western Alliance Bancorp, Genprex, Windtree Therapeutics, BridgeBio Pharma, or PacWest Bancorp? PR Newswire NEW YORK, April 19, 2023 NEW...
Globe Newswire
1 year ago
PALO ALTO, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 7, 2023, the compensation committee of BridgeBios board of ...
Globe Newswire
1 year ago
- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023 - Preliminary findings and study results will be presented in an oral presentation ...
Frequently Asked Questions
Frequently Asked Questions
What is Bridgebio Pharma Inc share price today?
plus_minus_icon
Can Indians buy Bridgebio Pharma Inc shares?
plus_minus_icon
How can I buy Bridgebio Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Bridgebio Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bridgebio Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Bridgebio Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Bridgebio Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bridgebio Pharma Inc?
plus_minus_icon
What percentage is Bridgebio Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bridgebio Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$27.06
$0.36
(1.35%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$54.32
$0.98 (1.84 %)
SpringWorks Therapeutics Inc
SpringWorks Therapeutics Inc
$38.04
$1.17 (3.17 %)
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
$25.33
$-0.55 (-2.13 %)
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc
$49.05
$-0.56 (-1.13 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$54.32
$0.98 (1.84 %)
SpringWorks Therapeutics Inc
SpringWorks Therapeutics Inc
$38.04
$1.17 (3.17 %)
Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals Inc
$25.33
$-0.55 (-2.13 %)
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc
$49.05
$-0.56 (-1.13 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00